125 related articles for article (PubMed ID: 37084495)
1. Therapy effect on AI-derived thalamic atrophy using clinical routine MRI protocol: A longitudinal, multi-center, propensity-matched multiple sclerosis study.
Jakimovski D; Silva D; Niels Bergsland ; Dwyer MG; Weinstock-Guttman B; Benedict RH; Riolo J; Zivadinov R;
Mult Scler Relat Disord; 2023 Jun; 74():104708. PubMed ID: 37084495
[TBL] [Abstract][Full Text] [Related]
2. Thalamic atrophy and dysconnectivity are associated with cognitive impairment in a multi-center, clinical routine, real-word study of people with relapsing-remitting multiple sclerosis.
Zivadinov R; Bergsland N; Jakimovski D; Weinstock-Guttman B; Lorefice L; Schoonheim MM; Morrow SA; Ann Picone M; Pardo G; Zarif M; Gudesblatt M; Nicholas JA; Smith A; Hunter S; Newman S; AbdelRazek MA; Hoti I; Riolo J; Silva D; Fuchs TA; Dwyer MG; Hb Benedict R
Neuroimage Clin; 2024; 42():103609. PubMed ID: 38718640
[TBL] [Abstract][Full Text] [Related]
3. Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes.
Jakimovski D; Zivadinov R; Bergsland N; Ramasamy DP; Hagemeier J; Genovese AV; Hojnacki D; Weinstock-Guttman B; Dwyer MG
Neuroimage Clin; 2021; 29():102554. PubMed ID: 33472143
[TBL] [Abstract][Full Text] [Related]
4. Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-word study is associated with disability progression.
Zivadinov R; Bergsland N; Jakimovski D; Weinstock-Guttman B; Benedict RHB; Riolo J; Silva D; Dwyer MG;
J Neurol Neurosurg Psychiatry; 2022 Jul; ():. PubMed ID: 35902228
[TBL] [Abstract][Full Text] [Related]
5. Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study.
Barnett M; Bergsland N; Weinstock-Guttman B; Butzkueven H; Kalincik T; Desmond P; Gaillard F; van Pesch V; Ozakbas S; Rojas JI; Boz C; Altintas A; Wang C; Dwyer MG; Yang S; Jakimovski D; Kyle K; Ramasamy DP; Zivadinov R
Neuroimage Clin; 2021; 32():102802. PubMed ID: 34469848
[TBL] [Abstract][Full Text] [Related]
6. Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis.
Dwyer MG; Silva D; Bergsland N; Horakova D; Ramasamy D; Durfee J; Vaneckova M; Havrdova E; Zivadinov R
Neuroimage Clin; 2017; 15():769-779. PubMed ID: 28706852
[TBL] [Abstract][Full Text] [Related]
7. DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis.
Dwyer M; Lyman C; Ferrari H; Bergsland N; Fuchs TA; Jakimovski D; Schweser F; Weinstock-Guttmann B; Benedict RHB; Riolo J; Silva D; Zivadinov R
Neuroimage Clin; 2021; 30():102652. PubMed ID: 33872992
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS.
Zivadinov R; Bergsland N; Korn JR; Dwyer MG; Khan N; Medin J; Price JC; Weinstock-Guttman B; Silva D;
AJNR Am J Neuroradiol; 2018 Feb; 39(2):289-295. PubMed ID: 29170269
[TBL] [Abstract][Full Text] [Related]
9. Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data.
Noteboom S; Strijbis EMM; Coerver EME; Colato E; van Kempen ZLE; Jasperse B; Vrenken H; Killestein J; Schoonheim MM; Steenwijk MD
Mult Scler Relat Disord; 2024 Jul; 87():105670. PubMed ID: 38772150
[TBL] [Abstract][Full Text] [Related]
10. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.
Horakova D; Cox JL; Havrdova E; Hussein S; Dolezal O; Cookfair D; Dwyer MG; Seidl Z; Bergsland N; Vaneckova M; Zivadinov R
J Neurol Neurosurg Psychiatry; 2008 Apr; 79(4):407-14. PubMed ID: 17550987
[TBL] [Abstract][Full Text] [Related]
11. Multisite MRI reproducibility of lateral ventricular volume using the NAIMS cooperative pilot dataset.
Jakimovski D; Zivadinov R; Bergsland N; Oh J; Martin M; Shinohara RT; Bakshi R; Calabresi PA; Papinutto N; Pelletier D; Dwyer MG
J Neuroimaging; 2022 Sep; 32(5):910-919. PubMed ID: 35384119
[TBL] [Abstract][Full Text] [Related]
12. Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
Sotirchos ES; Gonzalez-Caldito N; Dewey BE; Fitzgerald KC; Glaister J; Filippatou A; Ogbuokiri E; Feldman S; Kwakyi O; Risher H; Crainiceanu C; Pham DL; Van Zijl PC; Mowry EM; Reich DS; Prince JL; Calabresi PA; Saidha S
Mult Scler; 2020 Mar; 26(3):312-321. PubMed ID: 30741108
[TBL] [Abstract][Full Text] [Related]
13. Sex-Specific Differences in Life Span Brain Volumes in Multiple Sclerosis.
Jakimovski D; Zivadinov R; Bergsland N; Ramasamy DP; Hagemeier J; Weinstock-Guttman B; Kolb C; Hojnacki D; Dwyer MG
J Neuroimaging; 2020 May; 30(3):342-350. PubMed ID: 32392376
[TBL] [Abstract][Full Text] [Related]
14. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
[TBL] [Abstract][Full Text] [Related]
16. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
JAMA Neurol; 2022 Jul; 79(7):682-692. PubMed ID: 35575778
[TBL] [Abstract][Full Text] [Related]
17. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
18. Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis.
Dwyer MG; Bergsland N; Ramasamy DP; Weinstock-Guttman B; Barnett MH; Wang C; Tomic D; Silva D; Zivadinov R
J Neuroimaging; 2019 Sep; 29(5):615-623. PubMed ID: 31259467
[TBL] [Abstract][Full Text] [Related]
19. Late onset multiple sclerosis is associated with more severe ventricle expansion.
Jakimovski D; Dujmic D; Hagemeier J; Ramasamy DP; Bergsland N; Dwyer MG; Eckert S; Kolb C; Lizarraga A; Hojnacki D; Weinstock-Guttman B; Zivadinov R
Mult Scler Relat Disord; 2020 Nov; 46():102588. PubMed ID: 33296984
[TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
